Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. - Wikidata - awgldk - TriplyDB

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

http://www.wikidata.org/entity/Q34334873

about

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis Proteomics and mass spectrometry in the diagnosis of renal amyloidosis Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs Amyloid diseases of the heart: current and future therapies Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †Toward Optimization of the Second Aryl Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma Trapping of palindromic ligands within native transthyretin prevents amyloid formation First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out Amyloidosis: a convoluted story A putative role for cathepsin K in degradation of AA and AL amyloidosis Beyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen's chaperone activity Presence of variant transthyretin in aqueous humor of a patient with familial amyloidotic polyneuropathy after liver transplantation.Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.Long-term outcomes and complications of trabeculectomy for secondary glaucoma in patients with familial amyloidotic polyneuropathy Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study.Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR).Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis Transthyretin mutations in hyperthyroxinemia and amyloid diseases.α-Synuclein aggregation in the saliva of familial transthyretin amyloidosis: a potential biomarker.Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells.Recent progress in the understanding and treatment of transthyretin amyloidosis.Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers.Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.Clinical picture and outcome of transthyretin-related familial amyloid polyneuropathy (FAP) in Japanese patients.Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met.In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.Hereditary transthyretin amyloidosis from a Scandinavian perspective.Long term results of heart transplantation in patients with amyloid heart disease.Outcome of gastric emptying and gastrointestinal symptoms after liver transplantation for hereditary transthyretin amyloidosis.Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies.Applications of gene therapy for familial amyloidotic polyneuropathy.Targeting protein aggregation for the treatment of degenerative diseases

P2860

Q24562844-44EF7B9D-D2A5-48E5-B170-3D8F4C09D22D Q26764754-FD4BEBA6-41D6-4A77-974B-CE3706A00183 Q26776392-46F17A5C-2FC2-4F34-A7FB-50DFFD9AD6F1 Q27009309-D8333609-72AD-46C6-8297-E67B9928414E Q27023836-75A7D851-54C3-4331-A1F0-55F2A15D8DEA Q27652272-0631E068-C634-42EB-872E-EA404EA960BB Q27653642-B2A67EE1-E8A1-4FC7-BDD4-8EC1B5EDBAF9 Q27658823-4A66C3CA-48E7-4F86-9B54-9D169423CA74 Q27659009-89344495-04D5-4975-A2F4-F7BAD061B32F Q27665687-E54DE1B8-7364-4CE0-9308-EA6C676941FE Q28071522-7C403FD0-8676-4305-B69F-11A61DA430E0 Q28078350-EC02B096-AAEC-4BB5-B7CF-E60DBA4E9EFD Q28084013-8803D7FD-774F-41E9-885C-4369C71291F9 Q28215995-4FFAF021-9CF5-4275-AFEF-C0DEB39346DA Q28359732-88D8032A-BC6F-412B-8466-8949078A0E8A Q28477682-E835548A-65FC-4211-8CE8-A80EA1705F89 Q30884432-8202EDF7-AFDA-4AF3-A9DF-4E09F87140D0 Q33423160-DB3BB39A-4304-43DF-9B87-9662F9E00E9A Q33572696-8ED1DF8F-2CBB-4FC4-AED7-30E04E485049 Q33715284-A1521AD4-307B-4C13-A6A1-0CF0C32229B0 Q33734406-1934124B-1B4B-491A-86A4-4C190A5095AF Q33796862-22A93EE8-17DE-40EE-877B-AFF068A11AFF Q33991826-28CCC493-C622-4CD9-A14F-B6EE9D7F26B0 Q34078348-977BC2B3-FB8F-4AFD-9BDC-4F91A9766C4B Q34269382-85728A39-80A1-4BD4-88F3-7772E5A5E223 Q34271447-DA24C209-AA14-4F3C-8FAD-3552BA7600F6 Q34379778-4E2089A8-6DDB-4825-89F5-0D2188C9A193 Q34416193-4CE6D8F6-DEDC-4C96-AF0F-D1E401AAE5E5 Q34544072-06C16D94-CE97-4B3F-B9A0-F0097D0D230C Q34581917-0DCFD0CD-AEA5-4E0C-917B-323551566553 Q35054938-A4F3CDFE-F907-42EC-A674-5F5AD61FA349 Q35083244-DA5BDD20-D9AC-407F-B1DE-E3A2A965903C Q35119383-F0149A0E-1458-4327-8DC0-E2170769DA5C Q35203818-D8E488B8-4237-48CE-9212-E15959F5E80A Q35378115-79452561-D0D2-4A6D-89DC-8CCDE3B95D32 Q35556198-631FD8C6-286A-4F2C-920D-B6C89228027D Q35579265-1A14735B-7CBC-4096-9ED7-FE01A22B8910 Q35640323-C3F49E33-8852-4091-9210-14A42229D65C Q35907026-E72DEA4F-D927-4BDE-9063-5C7F4DAA8E21 Q36235980-9FC3FEB5-5991-43A8-A2F3-B7B33DF11636

P2860

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

http://www.wikidata.org/entity/Q34334873

description

1993 nî lūn-bûn

@nan

1993 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@ast

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@en

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@nl

type

label

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@ast

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@en

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@nl

prefLabel

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@ast

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@en

Clinical improvement and amylo ...... ary transthyretin amyloidosis.

@nl

P1433

Q34334873-DABF1565-BFCA-4805-B1D6-C1612A955A36

P1476

Q34334873-578A4A04-E844-4C80-90DF-A1298AD37BF5

P2093

Q34334873-00E815E2-33F5-41AD-9F34-B13667526D09

Q34334873-05A958E0-AD31-4919-8FDA-20F6FB07B91A

Q34334873-07E09B11-C43A-497F-8747-C0C7A7BEFA85

Q34334873-1478BFCA-E8C7-4A7E-944D-268D6F613FF0

Q34334873-29F4CF0E-B01B-4F96-AEFA-BCC2F0050C46

Q34334873-60AA20B2-CD97-4575-99F4-871AEC62B305

Q34334873-715AEE2C-7A9C-4B86-9CAE-392BEF5CF319

Q34334873-CD6DD36B-40E8-45AE-8340-B57B5529A926

Q34334873-D6D57E97-5DCE-43C7-A4B4-E2788AB080E7

P304

Q34334873-D2644FDC-BE90-423E-BF6C-200868A6ECA7

P31

Q34334873-FAECB0EE-0D45-4CC9-A388-FE390E075216

P356

Q34334873-DBB054B5-4345-450B-94FD-52CE9EBF6DDB

P407

Q34334873-AF0F354E-74AB-4A8A-9460-7C05EE1E5764

P433

Q34334873-401AB81C-F3C2-4F97-9AB7-A64D47368E02

P478

Q34334873-AD78F975-BE1A-4BC1-AF6B-C1A595435D53

P50

Q34334873-3BCCA333-F982-4B97-B137-1FF882CDDEFE

P577

Q34334873-E0C17B2F-2AED-4A8D-9479-C7AF9278B688

P698

Q34334873-0CD6DD09-83CB-4CDC-8392-42902169A93A

P921

Q34334873-7996C806-CB2E-48D4-86C4-373D6C7C0F30

P356

0140-6736(93)93127-M

P1433

P1476

Clinical improvement and amylo ...... tary transthyretin amyloidosis

@en

P2093

A Seymour

http://www.w3.org/2001/XMLSchema#string

B G Ericzon

http://www.w3.org/2001/XMLSchema#string

B G Wallin

http://www.w3.org/2001/XMLSchema#string

C G Groth

http://www.w3.org/2001/XMLSchema#string

G Holmgren

http://www.w3.org/2001/XMLSchema#string

L Steen

http://www.w3.org/2001/XMLSchema#string

O Andersen

http://www.w3.org/2001/XMLSchema#string

P N Hawkins

http://www.w3.org/2001/XMLSchema#string

S Richardson

http://www.w3.org/2001/XMLSchema#string

P304

1113-1116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/0140-6736(93)93127-M

http://www.w3.org/2001/XMLSchema#string

P407

P433

8853

http://www.w3.org/2001/XMLSchema#string

P478

341

http://www.w3.org/2001/XMLSchema#string

P50

P577

1993-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8097803

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation